Clinical trials: Grade II Glioma, open to volunteers
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of Pembrolizumab and M032 (NSC 733972)
This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma
- Trial name
- NCT05084430
- Testing
- M032, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Grade II Glioma, Grade III Glioma
Implantable Microdevice In Primary Brain Tumors
This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors.
- Conditions
- Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma
- Trial name
- NCT04135807
- Testing
- Microdevice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oliver Jonas
Glioma
Proton vs. Photon Radiotherapy for Patients With WHO Grade 2-3 Glioma
Patients with grade 2 and 3 gliomas who received photon radiation therapy as part of their standard treatment are at risk of developing cognitive impairments, depending on the tumor's location and the size of the target volume.
- Trial name
- GliProPh (NCT07750457)
- Testing
- Proton therapy, Photon therapy
- Where
- 2 sites in Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital, Essen
Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal.
- Conditions
- Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor
- Trial name
- NCT07416188
- Testing
- LMP744, Conventional Surgery or Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV…
- Conditions
- Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, WHO Grade 2 Glioma
- Trial name
- NCT06964737
- Testing
- Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Low Grade Glioma
Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma
Low-grade glioma (LGG) represent typically slowly growing primary brain tumors with world health organization (WHO) grade I or II who affect young adults around their fourth decade.
- Trial name
- INDIGO (NCT05964569)
- Testing
- model-guided optimization of treatment plan, standard treatment plan, no optimization
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital Heidelberg
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back…
- Trial name
- NCT06160206
- Testing
- Bevacizumab, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- Academic and Community Cancer Research United
Low Grade Glioma
A Vaccine Trial for Low Grade Gliomas
The study will assess the immunogenicity, safety and preliminary clinical efficacy of the glioma associated antigen (GAA)/tetanus toxoid (TT) peptide vaccine and poly-ICLC in HLA-A2+ children with unresectable low-grade gliomas…
- Trial name
- NCT02358187
- Testing
- Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- James Felker
Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
- Conditions
- Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG
- Trial name
- NCT06838676
- Testing
- ACT001
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- Nationwide Children's Hospital
Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib…
- Conditions
- Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma
- Trial name
- NCT07703436
- Testing
- Safusidenib
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Nuvation Bio Inc.
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent).
- Conditions
- Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)
- Trial name
- NCT04485559
- Testing
- Everolimus, Trametinib
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Targeted Pediatric High-Grade Glioma Therapy
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT05839379
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 350 people
- Sponsor
- Nationwide Children's Hospital
Low Grade Astrocytoma, Low Grade Glioma
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that…
- Conditions
- Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma
- Trial name
- NCT04166409
- Testing
- Biospecimen Collection, Carboplatin, Echocardiography Test
- Where
- 132 sites in United States, Canada and 1 more
- Volunteers
- 170 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Astrocytoma, Grade III
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
- Trial name
- NCT03596086
- Testing
- ADV/HSV-tk (gene therapy)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- David Baskin MD
Glioma, Astrocytoma, Grade IV
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health…
- Conditions
- Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
- Trial name
- SIGMA (NCT05303519)
- Testing
- safusidenib
- Where
- 61 sites in United States, Australia and 1 more
- Volunteers
- 365 people
- Sponsor
- Nuvation Bio Inc.
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent).
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Trial name
- NCT06410248
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Northwestern University
Oligodendroglioma
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).
Oligodendrogliomas in the novel edition of the Central Nervous System (CNS) World Health Organization (WHO) classification are now molecularly defined by isocitrate dehydrogenase (IDH)1 or IDH2 mutations and 1p/19q co-deletion.
- Trial name
- ImproveCodel (NCT05331521)
- Testing
- CETEG, PCV, RT
- Where
- 19 sites in Germany
- Volunteers
- 406 people
- Sponsor
- University Hospital Heidelberg
Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4
A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)
The study aims to investigate the combination of the IDH1R132H peptide vaccine and the dual IDH1/2 inhibitor vorasidenib in patients with recurrent and/or progressive astrocytoma, WHO grade 2,3 and 4.
- Trial name
- iVOCAL (NCT07877415)
- Testing
- IDH1R132H-vac, Vorasidenib 40 mg Oral Tablet, Aldara - Imiquimod 5%
- Volunteers
- 45 people
- Sponsor
- Heidelberg University
Glioma, Glioma of Brain
Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared
The study aims to assess the direct patient-reported perception (PROs) of individuals affected by IDH-mutant, grade 2 gliomas undergoing radiotherapy or pharmacological treatment with vorasidenib.
- Conditions
- Glioma, Glioma of Brain, Low Grade Glioma of Brain, Low Grade Gliomas
- Trial name
- LGG PRO's (NCT07547163)
- Testing
- Vorasidenib, Radiotherapy, active surveillance
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma.
- Conditions
- Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
- Trial name
- NCT04540107
- Testing
- Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Susan Chang